177 related articles for article (PubMed ID: 17520584)
21. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
Herbst RS; Kim ES; Harari PM
Expert Opin Biol Ther; 2001 Jul; 1(4):719-32. PubMed ID: 11727507
[TBL] [Abstract][Full Text] [Related]
22. Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.
Chan A; Teoh D; Sanghera P; Hartley A
Radiother Oncol; 2009 Dec; 93(3):654. PubMed ID: 19524312
[No Abstract] [Full Text] [Related]
23. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab plus radiotherapy for head and neck cancer.
Ho AC
N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16707760
[No Abstract] [Full Text] [Related]
25. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
[TBL] [Abstract][Full Text] [Related]
27. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
Bourhis J; Lefebvre JL; Vermorken JB
Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
[TBL] [Abstract][Full Text] [Related]
29. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).
Walsh L; Gillham C; Dunne M; Fraser I; Hollywood D; Armstrong J; Thirion P
Radiother Oncol; 2011 Jan; 98(1):38-41. PubMed ID: 21159400
[TBL] [Abstract][Full Text] [Related]
30. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
31. Treatment of advanced head and neck cancer with cetuximab.
Merlano M; Garrone O
Int J Biol Markers; 2007 S4 - Jan-Mar; 22(4):71-76. PubMed ID: 28207117
[TBL] [Abstract][Full Text] [Related]
32. [Role of targeted therapy in the treatment of squamous cell head and neck cancer].
Gyergyay F
Magy Onkol; 2007; 51(2):155-7. PubMed ID: 17660872
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
Li JZ; Zheng JW; Zhang ZY
Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.
Forastiere AA; Burtness BA
J Clin Oncol; 2007 Jun; 25(16):2152-5. PubMed ID: 17538157
[No Abstract] [Full Text] [Related]
35. Manageable early toxicity of cetuximab concurrent with radical radiotherapy for locally advanced head and neck cancer.
Wieczorek A; Hamid A; O'Toole L
Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):496. PubMed ID: 21482459
[No Abstract] [Full Text] [Related]
36. Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Merlano M; Occelli M
Ther Clin Risk Manag; 2007 Oct; 3(5):871-6. PubMed ID: 18473010
[TBL] [Abstract][Full Text] [Related]
37. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
38. Are anti-vitamin K drugs contraindicated with cetuximab during head-and-neck cancer concomitant radiotherapy?
Brohée D; Henry AR; Castadot P
Acta Clin Belg; 2013; 68(3):237-9. PubMed ID: 24156231
[TBL] [Abstract][Full Text] [Related]
39. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
Panikkar RP; Astsaturov I; Langer CJ
Cancer Invest; 2008 Feb; 26(1):96-103. PubMed ID: 18181051
[TBL] [Abstract][Full Text] [Related]
40. EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?
Alorabi M; Shonka NA; Ganti AK
Crit Rev Oncol Hematol; 2016 Mar; 99():170-9. PubMed ID: 26797287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
